PRKDC and osteosarcoma: Furthermore, there was an increase in the percentage of apoptotic osteosarcoma cells in the si‐PRKDC+ anlotinib group relative to that in the group receiving anlotinib alone, as detected via flow cytometry (Figure 1G).